42 U.S.C. § 287a–2
Rare disease regional centers of excellence
United States · Title 42 — THE PUBLIC HEALTH AND WELFARE · Status: effective
Cite this
- Citation
- 42 U.S.C. § 287a–2, Rare disease regional centers of excellence, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/475706
- Permanent ID
ys:prov:475706@1- SHA-256
8089338003de8889a48918047dabc067db2d4b5997e10cf01afcbb8859e558d3
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
The Director of the Office of Rare Diseases (in this section referred to as the “Director”), in collaboration with the directors of the other relevant institutes and centers of the National Institutes of Health, may enter into cooperative agreements with and make grants to public or private nonprofit entities to pay all or part of the cost of planning, establishing, or strengthening, and providing basic operating support for regional centers of excellence for clinical research into, training in, and demonstration of diagnostic, prevention, control, and treatment methods for rare diseases.
A cooperative agreement or grant under paragraph (1) shall be entered into in accordance with policies established by the Director of NIH.
The Director shall coordinate the activities under this section with similar activities conducted by other national research institutes, centers and agencies of the National Institutes of Health and by the Food and Drug Administration to the extent that such institutes, centers and agencies have responsibilities that are related to rare diseases.
Federal payments made under a cooperative agreement or grant under subsection (a) may be used for—
Support of a center under subsection (a) may be for a period of not to exceed 5 years. Such period may be extended by the Director for additional periods of not more than 5 years if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director and if such group has recommended to the Director that such period should be extended.
Legislative history
The public laws that enacted or amended this section. Tallies are for the whole bill as it passed each chamber — often an omnibus covering far more than this provision — not a vote on this section alone.
- Rare Diseases Act of 2002House: no recorded tallySenate: no recorded tally
- National Institutes of Health Reform Act of 2006House: 414–2Senate: no recorded tally
- Consolidated Appropriations Act, 2012